Longeveron Inc. (NASDAQ:LGVN – Free Report) – Equities research analysts at HC Wainwright lifted their Q2 2024 earnings per share estimates for Longeveron in a research report issued on Monday, July 29th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($1.12) for the quarter, up from their prior estimate of ($1.17). HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($3.67) per share. HC Wainwright also issued estimates for Longeveron’s Q3 2024 earnings at ($0.70) EPS, Q4 2024 earnings at ($0.53) EPS, FY2024 earnings at ($3.12) EPS, Q1 2025 earnings at ($0.46) EPS, Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS and FY2025 earnings at ($1.49) EPS.
Longeveron Trading Down 2.9 %
Shares of NASDAQ LGVN opened at $3.04 on Wednesday. The stock has a fifty day simple moving average of $2.28 and a two-hundred day simple moving average of $3.48. Longeveron has a 1-year low of $0.77 and a 1-year high of $35.60. The firm has a market cap of $36.84 million, a price-to-earnings ratio of -0.32 and a beta of 0.43.
Hedge Funds Weigh In On Longeveron
An institutional investor recently bought a new position in Longeveron stock. Armistice Capital LLC purchased a new position in Longeveron Inc. (NASDAQ:LGVN – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 1,836,000 shares of the company’s stock, valued at approximately $2,497,000. Armistice Capital LLC owned 7.31% of Longeveron at the end of the most recent reporting period. Institutional investors and hedge funds own 10.01% of the company’s stock.
About Longeveron
Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.
Read More
- Five stocks we like better than Longeveron
- CD Calculator: Certificate of Deposit Calculator
- First Solar Stock: The Dawn of a New Rally in Share Prices
- How to Buy Cheap Stocks Step by Step
- Mastercard Stock’s Q2 Financial Results Outshine Competitors
- Best Aerospace Stocks Investing
- Tobacco Giant’s Shares Fall on EPS Miss, Lackluster Pouch Gains
Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.